RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology

Our Bureau

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited to present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session by the American College of Rheumatology(RA). According to the abstract, this Phase III, randomized, double-blind study evaluated the efficacy and safety of telitacicept 160 mg group versus the placebo group in RA patients with inadequate responses to MTX. The study met all its primary endpoints and showed comparable safety profile of telitacicept group vs. control group. Interested parties are welcome to attend Remegen’s presentation session on Wednesday, November 15 from 7:30 a.m. to 9:00 a.m.(PST) at ACR Convergence 2023 at the San Diego Convention Center in California.

The invitation to present at ACR Convergence 2023 follows a recent announcement that the Company’s cutting-edge drug telitacicept (RC18) obtained positive results in a Phase III clinical study in the treatment of patients with rheumatoid arthritis in China. Telitacicept is an innovative B-cell lymphocyte stimulator/proliferation inducing ligand(BLyS/APRIL) dual-target fusion protein drug independently developed by RemeGen that can prevent abnormal differentiation of B cells by simultaneously inhibiting the overexpression of two cytokines, BLyS and APRIL, thereby treating a variety of immunology diseases mediated by B cells.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Ocutrx Unveils OcuLenz AR/XR Headset, Aiding Vision for Patients with Advanced Macular Degeneration

Ocutrx Technologies, Inc., a leader in augmented reality (AR) and 3D technology for medical and surgical applications, today is pulling back the curtain on its latest innovation: OcuLenz™, its groundbreaking AR/XR headset. OcuLenz is engineered to enhance visual clarity for individuals living with advanced macular degeneration (AMD). This innovative AR/XR headset […]
OcuLenz AR/XR Headset for Macular Degeneration Patients

Subscribe Now